Full history for every metric is available with a Kvantra account

Stock profile
argenx SE logo

argenx SE (ARGX)

Country: NetherlandsSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
25.6
Market cap
58.21B
Currency USD
KvantraRankAbout18
IValue13
IIQuality22
IIIMomentum18
Current price
925.70 USD-1.73%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m411,0784111,2262,1904,1534,5376,409
Operating profit$m1,0551,700
Net profit$m-608-408-710-2958331,2921,3451,889
EPS reported$19.6320.82
Operating cashflow per share$11.1815.53
Capex per share$0.100.06
FCF per share$11.0815.47
Free cash flow$m6791,156
Net debt$m-4,357-5,137
Book value equity$m7,3238,417
Book value per share$110.9129.7
Number of sharesm66.0364.89
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx42.84-
P/B LTMx7.046.92
P/S LTMx12.419.67
P/FCF LTMx75.9150.37
EV/EBITDA LTMx36.7231.96
EV/Sales LTMx11.598.81
Earnings Yield LTM%2.33%2.26%
FCF Yield%1.32%1.99%
Quality
ROE%17.64%16.86%
ROIC%14.30%13.96%
Operating margin%25.39%29.35%
Gross margin%89.15%90.49%
FCF/Sales%16.35%21.67%
Growth and momentum
EPS Growth YoY%+53.60%+170.04%
Sales Growth YoY%+89.64%+156.47%
Net Income Growth YoY%+55.10%+272.45%
FCF Growth%-+144.05%
Operating Profit Growth%-+380.08%
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx8.1324.59
Net Debt/EBITDAx-2.60-2.55
EBIT/Net interestx258.36443.95
Net debt/market cap%-8.45%-8.82%
Net debt/Equityx-0.59-0.61
Gross debt/equityx0.010.01

ETFs that hold argenx

FundTickerPosition#Weight
iShares Biotechnology ETFIBB63.77%
First Trust NYSE Arca Biotechnology Index FundFBT73.80%
iShares MSCI Europe Health Care Sector UCITS ETFESIH.DE83.10%
iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4.DE82.97%
State Street SPDR MSCI Europe Health Care UCITS ETFHLTH.L83.09%
Dynamic Active Global Dividend ETFDXG.TO54.49%
VanEck Biotech ETFBBH64.51%
Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE.DE83.11%
iShares MSCI Belgium ETFEWK216.55%
Nomura Focused International Core ETFEXUS93.23%

Funds with argenx among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price925.70 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.

Websiteargenx.com
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

argenx SE (ARGX)

ARGX · NASDAQ · Healthcare
925.70 USD-1.73%
Sign up to track this stock
Benchmarks
KvantraRank18
Market cap58.21B
P/E NTM25.6
P/E TTMN/A
KvantraRank?18 / 100
Value
13
Quality
22
Momentum
18
Financialsin USD
20242025TTM2026E
ETFs that hold argenx
FundTickerPosition#Weight
iShares Biotechnology ETFIBB63.77%
First Trust NYSE Arca Biotechnology Index FundFBT73.80%
iShares MSCI Europe Health Care Sector UCITS ETFESIH.DE83.10%
iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4.DE82.97%
State Street SPDR MSCI Europe Health Care UCITS ETFHLTH.L83.09%
Dynamic Active Global Dividend ETFDXG.TO54.49%
VanEck Biotech ETFBBH64.51%
Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE.DE83.11%
iShares MSCI Belgium ETFEWK216.55%
Nomura Focused International Core ETFEXUS93.23%

Funds with argenx among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current925.70 USD
Upside
Price consensus
Last year average price target
Current price925.70 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III trials for several indications, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. Furthermore, efgartigimod is progressing through Phase II/III clinical trials for bullous pemphigoid and idiopathic inflammatory myopathy, with its subcutaneous ENHANZE formulation also undergoing preclinical assessment. Beyond its lead product, argenx SE maintains an active pipeline of immunology-focused programs. This includes cusatuzumab, targeted at hematological cancers and high-risk myelodysplastic syndromes (MDS); ARGX-119, an antibody designed to inhibit muscle-specific tyrosine kinase; ARGX-117, slated for severe autoimmune disorders; ARGX-118, aimed at mitigating airway inflammation; and ARGX-120, another candidate for the treatment of autoimmune diseases. The firm also engages in collaborations for additional investigational products, such as ARGX-115 for cancer therapy, ARGX-112 which targets the interleukin-22 receptor, and ARGX-114, an antibody engineered to block the MET receptor. argenx SE has forged strategic alliances with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S. It also holds numerous collaboration and licensing agreements with partners including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., the University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. Established in 2008, argenx SE is headquartered in Breda, the Netherlands.

Websiteargenx.com
IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free